The FDA approved topical Hyftor for the treatment of facial angiofibroma in patients who have tuberous sclerosis complex, Nobelpharma America LLC announced in a press release.
Hyftor (sirolimus topical gel) 0.2%, which previously received orphan drug status, is the first topical treatment indicated for the treatment of facial angiofibroma in tuberous sclerosis complex.
A genetic disorder that causes tumors in many organs, tuberous sclerosis complex primarily affects the brain, eyes, heart, kidneys, skin and lungs. Approximately 75% to 80% of those with the disease will experience facial